NexGenix Pharmaceuticals

NexGenix Pharmaceuticals was a biopharmaceutical company focused on the discovery and development of small molecule therapeutics for the treatment of neurofibromatosis and related oncology indications. The company's primary research centered on targeting the molecular pathways associated with Neurofibromatosis type 2 (NF2), specifically focusing on p21-activated kinase (PAK) inhibitors and HSP90 inhibitors. Despite early-stage development efforts and collaborations with academic institutions like the House Ear Institute, the company appears to have ceased active operations. Its pipeline was designed to address unmet needs in rare genetic disorders characterized by the growth of tumors along nerves.